Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus plus prednisone for Erdheim-Chester disease
ACTRN12613001321730Phase 2Active, not recruiting
- Sponsor
- University of Parma
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus and prednisone in Erdheim-Chester disease (ECD), sponsored by University of Parma. Primary endpoints: Mortality and Disease progression, regression, or stabilization. Started Dec 2007; status: active, not recruiting.
02
Drugs
sirolimusprednisone
03
Conditions
Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on ACTRN12613001321730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001321730.